The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial

International Journal of Clinical Practice

Volumn 65, Issue 11, 2011, Pages 1132-1140

  Al Sifri, S ^a   Basiounny, A ^b   Echtay, A ^c   Al Omari, M ^d   Harman Boehm, I ^e   Kaddaha, G ^f   Al Tayeb, K ^g   Mahfouz, A S ^h   Al Elq, A ⁱ   Radican, L ^j   Ozesen C ^j   Katzeff, H L ^j   Musser, B J ^j   Suryawanshi, S ^j   Girman, C J ^j   Davies, M J ^j   Engel, S S ^j  

^a AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^b Diabetes Institute   (Egypt)

^c RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^d JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f RASHID HOSPITAL   (United Arab Emirates)

^g AL NOOR SPECIALIST HOSPITAL   (Saudi Arabia)

^h Bugshan Hospital   (Saudi Arabia)

ⁱ IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; METFORMIN; SITAGLIPTIN;

ACUTE PANCREATITIS; ADULT; AGED; ASTHENIA; BRAIN ISCHEMIA; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIET RESTRICTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SOMNOLENCE; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; FASTING; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; ISLAM; MALE; MIDDLE AGED; MIDDLE EAST; PYRAZINES; RESIDENCE CHARACTERISTICS; SULFONYLUREA COMPOUNDS; TRIAZOLES; YOUNG ADULT;

EID: 80054706899     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02797.x     Document Type: Review

References (24)

1. Cryer PE,. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-76.
2. Al Arouj M, Assaad-Khalil S, Buse J, et al., Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010; 33: 1895-902.
3. Karamat MA, Syed A, Hanif W,. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010; 103: 139-47.
4. Salti I, Benard E, Detournay B, et al., A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27: 2306-11. (Pubitemid 39281377)
5. Inzucchi SE,. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72. (Pubitemid 34256388)
6. Malik S, Lopez V, Chen R, Wu W, Wong ND,. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007; 77: 126-33. (Pubitemid 46590472)
7. van Staa T, Abenhaim L, Monette J,. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-41. (Pubitemid 27341824)
8. Del Prato S, Pulizzi N,. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006; 55 (Suppl. 1): S20-7.
9. Aravind SR, Tayeb K, Ismail SB, et al., Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin 2011; 27: 1237-42.
10. Devendra D, Gohel B, Bravis V, et al., Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446-50.
11. Hassanein M, Hanif W, Malik W, et al., Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011; 27: 1367-74.
12. Mafauzy M,. Repaglinide vs. glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45-53. (Pubitemid 34823624)
13. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE,. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-7. (Pubitemid 44912190)
14. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-43. (Pubitemid 44912191)
15. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE,. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-87. (Pubitemid 47219404)
16. Williams-Herman D, Johnson J, Teng R, et al., Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-51.
17. Williams-Herman D, Engel SS, Round E, et al., Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
18. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205. (Pubitemid 46206563)
19. Seck T, Nauck MA, Sheng D, et al., Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-76.
20. Arechavaleta R, Seck T, Chen Y, et al., Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13: 160-8.
21. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705. (Pubitemid 46048557)
22. Schernthaner G, Grimaldi A, Di Mario U, et al., GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-42. (Pubitemid 39120222)
23. Cesur M, Corapcioglu D, Gursoy A, et al., A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007; 75: 141-7. (Pubitemid 44894596)
24. Sari R, Balci MK, Akbas SH, Avci B,. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004; 30: 169-77. (Pubitemid 39243119)